Jeannette Jakus, MD
Dermatology · Brooklyn, NYNPI 1477711422
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.4%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Galderma Laboratories, L.p. at 43.7% of the total. 2025 is the largest year on record at $41,344, more than ten times the $1,203 reported in 2019. Among dermatology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 123 payments — averaging $644.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Galderma Laboratories, L.p.$35K
- Incyte Corporation$23K
- Arcutis Biotherapeutics, Inc.$8K
- AbbVie$5K
- UCB, Inc.$3K
- E.r. Squibb & Sons, L.L.C.$2K
- plus $4K from 21 others
Across 503 payments — averaging $1867.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$349K
- Regeneron$164K
- Dermavant Sciences, Inc.$125K
- Pfizer$121K
- Amgen$85K
- Arcutis Biotherapeutics, Inc.$32K
- plus $63K from 4 others
What the payments were for
- Consulting fees$32,80941%
- Speaking & faculty fees$41,55052%
- Travel & lodging$9911%
- Food & beverage$3,8135%
- Education$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Galderma Laboratories, L.p. | 22 | $34,661 |
| Incyte Corporation | 28 | $22,773 |
| Arcutis Biotherapeutics, Inc. | 4 | $7,535 |
| AbbVie | 8 | $4,803 |
| UCB, Inc. | 3 | $2,774 |
| E.r. Squibb & Sons, L.L.C. | 6 | $2,426 |
| Pierre Fabre Pharmaceuticals, Inc. | 1 | $2,000 |
| Johnson & Johnson | 9 | $467 |
| Dermavant Sciences, Inc. | 5 | $347 |
| Janssen Scientific Affairs, LLC | 4 | $332 |
| Merz North America, Inc. | 2 | $197 |
| Lilly USA, LLC | 4 | $135 |
| Abeona Therapeutics, Inc. | 1 | $120 |
| Sanofi | 4 | $98 |
| Novartis | 4 | $97 |
| Pfizer | 4 | $88 |
| Organon | 2 | $77 |
| Amgen | 2 | $56 |
| Regeneron | 1 | $47 |
| Regeneron Healthcare Solutions, Inc. | 2 | $42 |
| Nobelpharma America, LLC | 1 | $30 |
| VYNE Pharmaceuticals Inc. | 1 | $30 |
| Chiesi USA, Inc. | 1 | $27 |
| LEO Pharma Inc. | 1 | $27 |
| Sanofi-aventis U.S. LLC | 1 | $25 |
| Boehringer Ingelheim | 1 | $25 |
| Bristol Myers Squibb | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$79,262 in reported general payments places this provider in the 90th percentile of 1,151 dermatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf)Adalimumab | 14 | $181,426 |
| Dupixent PenDupilumab | 22 | $78,800 |
| OpzeluraRuxolitinib Phosphate | 16 | $30,218 |
| ZoryveRoflumilast | 17 | $13,962 |
| Tacrolimus | 24 | $3,636 |
| Pimecrolimus | 11 | $2,573 |
| Clobetasol Propionate | 43 | $2,497 |
| Ketoconazole | 76 | $2,087 |
| Triamcinolone Acetonide | 72 | $1,138 |
| Fluocinolone Acetonide | 21 | $581 |
| Clindamycin Phosphate | 14 | $352 |
| Doxycycline Hyclate | 14 | $264 |
| Hydrocortisone | 29 | $188 |
| Mupirocin | 16 | $120 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieHumira(Cf) | $4,803 | $181,42614 claims |
| Incyte CorporationOpzelura | $22,773 | $30,21816 claims |
| Arcutis Biotherapeutics, Inc.Zoryve | $7,535 | $13,96217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,151 dermatology providers in New York.
Other dermatology in Brooklyn
- Hilary BaldwinBrooklyn$1.5M
- Steven BaranowitzBrooklyn$625K
- Susan BardBrooklyn$425K
- Nanette SilverbergBrooklyn$337K
- Alexandra GolantNew York$3.6M
- David CohenNew York$3M
- Michael CameronNew York$2.6M
- Saakshi KhattriNew York$2.4M
- Amy WechslerNew York$2.4M
- Jeffrey WeinbergKew Gardens$2.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.